Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

55.85
+2.815.30%
Post-market: 55.940.0867+0.16%19:59 EDT
Volume:2.35M
Turnover:131.25M
Market Cap:8.55B
PE:20.17
High:57.61
Open:53.12
Low:53.11
Close:53.04
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:1.62
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:14.15
PE(LYR):20.16

Loading ...

TG Therapeutics is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jul 28

B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating

MT Newswires Live
·
Jul 27

TG Therapeutics Inc : B. Riley Raises Target Price to $86 from $55

THOMSON REUTERS
·
Jul 27

Analyst Tara Bancroft Raises TG Therapeutics Price Target to $75 on Strong Long-Term Briumvi Growth Outlook

TIPRANKS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), McKesson (MCK) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 22

TG Therapeutics Targets Myasthenia Gravis Growth With New BRIUMVI Trial

TIPRANKS
·
Jul 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX), Protagonist Therapeutics (PTGX) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Jul 16

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 14

TG Therapeutics Inc : JP Morgan Raises Target Price to $65 from $46

THOMSON REUTERS
·
Jul 14

TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jul 13

TG Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 13

Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says

MT Newswires Live
·
Jul 07

BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating

MT Newswires Live
·
Jul 07

TG Therapeutics price target raised to $20 from $17 at BofA

TIPRANKS
·
Jul 07

TG Therapeutics Price Target Maintained with a $70.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 07

TG Therapeutics: Buy Rating Reaffirmed as Briumvi Schizophrenia Trial Adds Upside Optionality; $70 Price Target Unchanged

TIPRANKS
·
Jul 06

TG Therapeutics initiates Briumvi clinical trial

TIPRANKS
·
Jul 06

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating Briumvi in Patients with Treatment-resistant Schizophrenia

THOMSON REUTERS
·
Jul 06

TG Therapeutics (TGTX) Gains Momentum As The Fair Value Narrative Turns More Cautious

Simply Wall St.
·
Jun 26

TG Therapeutics price target raised to $83 from $57 at Jefferies

TIPRANKS
·
Jun 23